# EDGAR Filing Document

**Accession Number:** 0001484565
**File Stem:** 0001193125-26-228052
**Filing Date:** 2026-5
**Character Count:** 13340
**Document Hash:** a1c1d944eaf09d333a54cad5fae63c63
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-228052.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001193125-26-228052

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**EFFECTIVENESS DATE**: 20260518

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOLENO THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001484565
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770523891
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270785
- **FILM NUMBER:** 26991028

**BUSINESS ADDRESS:**
- **STREET 1:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-213-8444

**MAIL ADDRESS:**
- **STREET 1:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Capnia, Inc.
- **DATE OF NAME CHANGE:** 20100219

**As filed with the Securities and Exchange Commission on May 18, 2026**

**Registration No. 333-200175** 

**Registration No. 333-210563** 

**Registration No. 333-220056** 

**Registration No. 333-224070** 

**Registration No. 333-230402** 

**Registration No. 333-235999** 

**Registration No. 333-239496** 

**Registration No. 333-252014** 

**Registration No. 333-264035** 

**Registration No. 333-270785** 

**Registration No. 333-273816** 

**Registration No. 333-276548** 

**Registration No. 333-276785** 

**Registration No. 333-281339** 

**Registration No. 333-285435** 

**Registration No. 333-293756** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-200175** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210563** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-220056** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224070** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230402** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-235999** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-239496** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-252014** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-264035** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270785** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-273816** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-276548** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-276785** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-281339** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285435** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-293756** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Soleno Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **77-0523891** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(IRS employer**<br> **identification number)** |

---

**100 Marine Parkway, Suite 400** 

**Redwood City, CA 94065** 

**(Address of Principal Executive Offices)** 

**2014 Equity Incentive Plan, as amended and restated** 

**2014 Employee Stock Purchase Plan** 

**2020 Inducement Equity Incentive Plan, as amended** 

**(Full title of the Plans)** 

**Darin M. Lippoldt** 

**President and Secretary** 

**Soleno Therapeutics, Inc.** 

**6027 Edgewood Bend Court** 

**San Diego, California 92130** 

**(Name and address of agent for service)** 

**(858) 617-7600** 

**(Telephone number, including area code, of agent for service)** 

***With a copy to:***

**Jamie Leigh** 

**Kevin Cooper** 

**Carlos Ramirez** 

**Cooley LLP** 

**3 Embarcadero Center, 20th Floor** 

**San Francisco, California 94111** 

**(415) 693-2000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**DEREGISTRATION OF SECURITIES** 

These Post-Effective Amendments (these "Post-Effective Amendments") are being filed by Soleno Therapeutics, Inc. (the "Registrant") to deregister all shares of the Registrant's common stock, par value $0.001 per share ("Shares"), that remain unissued under the following Registration Statements on Form S-8 (each, a "Registration Statement", and collectively, the "Registration Statements") previously filed by the Registrant with the U.S. Securities and Exchange Commission (the "SEC"):

• [Registration Statement No. 333-200175](http://www.sec.gov/Archives/edgar/data/1484565/000119312514411110/d774170ds8.htm) pertaining to the registration of (i) 334,750 Shares (as adjusted to reflect the one-for-five (1-for-5) reverse stock split that became effective on October 6, 2017 (the "Reverse Stock Split")) issuable under the Registrant's 2014
Equity Incentive Plan (the "2014 Plan"), and (ii) 27,967 Shares (as adjusted to reflect the Reverse Stock Split) issuable under the Registrant's 2014 Employee Stock Purchase Plan (the "2014 ESPP"), which was filed with
the SEC on November 13, 2014.

• [<u>Registration Statement No.</u> <u>333-210563</u>](http://www.sec.gov/Archives/edgar/data/1484565/000119312516528014/d172303ds8.htm) pertaining to the registration of (i) 166,296 Shares (as adjusted to reflect the Reverse Stock Split) issuable under the 2014 Plan and (ii) 41,574 Shares (as adjusted
to reflect the Reverse Stock Split) issuable under the 2014 ESPP, which was filed with the SEC on April 1, 2016.

• [Registration Statement No. 333-220056](http://www.sec.gov/Archives/edgar/data/1484565/000162828017008794/soleno-sx82017.htm) pertaining to the registration of 1,920,133 Shares (as adjusted to reflect the Reverse Stock Split) issuable under the 2014 Plan, which was filed with the SEC on August 18,
2017

• [Registration Statement No. 333-224070](http://www.sec.gov/Archives/edgar/data/1484565/000119312518104067/d561331ds8.htm) pertaining to the registration of 223,742 Shares issuable under the 2014 Plan, which was filed with the SEC on April 2, 2018.

• [Registration Statement No. 333-230402](http://www.sec.gov/Archives/edgar/data/1484565/000119312519079815/d722339ds8.htm) pertaining to the registration of 223,742 Shares issuable under the 2014 Plan, which was filed with the SEC on March 20, 2019.

• [Registration Statement No. 333-235999](http://www.sec.gov/Archives/edgar/data/1484565/000119312520011155/d860996ds8.htm) pertaining to the registration of 223,742 Shares issuable under the 2014 Plan, which was filed with the SEC on January 21, 2020.

• [Registration Statement No. 333-239496](http://www.sec.gov/Archives/edgar/data/1484565/000119312520181089/d903436ds8.htm) pertaining to the registration of 2,000,000 Shares issuable under the Registrant's Amended and Restated 2014 Equity Incentive Plan ("A&R 2014 Plan"), which was
filed with the SEC on June 26, 2020.

• [Registration Statement No. 333-252014](http://www.sec.gov/Archives/edgar/data/1484565/000119312521006302/d74283ds8.htm) pertaining to the registration of (i) 3,184,627 Shares issuable under the Registrant's A&R 2014 Plan and (ii) 1,500,000 Shares issuable under the Registrant's 2020
Inducement Equity Incentive Plan ("2020 Inducement Plan"), which was filed with the SEC on January 11, 2021.

• [Registration Statement No. 333-264035](http://www.sec.gov/Archives/edgar/data/1484565/000119312522092069/d330778ds8.htm) pertaining to the registration of 3,194,572 Shares issuable under the Registrant's A&R 2014 Plan, which was filed with the SEC on March 31, 2022.

• [Registration Statement No. 333-270785](http://www.sec.gov/Archives/edgar/data/1484565/000119312523077855/d480282ds8.htm) pertaining to the registration of (i) 238,329 Shares issuable under the Registrant's A&R 2014 Plan and (ii) 500,000 Shares issuable under the Registrant's 2020
Inducement Plan, which was filed with the SEC on March 23, 2023.

• [Registration Statement No. 333-273816](http://www.sec.gov/Archives/edgar/data/1484565/000119312523206356/d584124ds8.htm) pertaining to the registration of 1,800,000 Shares issuable under the Registrant's A&R 2014 Plan, which was filed with the SEC on April 8, 2023.

• [Registration Statement No. 333-276548](http://www.sec.gov/Archives/edgar/data/1484565/000119312524009247/d677869ds8.htm) pertaining to the registration of 1,000,000 Shares issuable under the Registrant's A&R 2014 Plan, which was filed with the SEC on January 17, 2024.

• [Registration Statement No. 333-276785](http://www.sec.gov/Archives/edgar/data/1484565/000119312524020926/d805916ds8.htm) pertaining to the registration of 500,000 Shares issuable under the Registrant's 2020 Inducement Plan, as amended, which was filed with the SEC on January 31, 2024.

------

• [Registration Statement No. 333-281339](http://www.sec.gov/Archives/edgar/data/1484565/000119312524195991/d866711ds8.htm) pertaining to the registration of 2,000,000 Shares issuable under the Registrant's A&R 2014 Plan, which was filed with the SEC on August 7, 2024.

• [Registration Statement No. 333-285435](http://www.sec.gov/Archives/edgar/data/1484565/000119312525042545/d903784ds8.htm) pertaining to the registration of 1,828,152 Shares issuable under the Registrant's A&R 2014 Plan, which was filed with the SEC on January 28, 2025.

• [Registration Statement No. 333-293756](http://www.sec.gov/Archives/edgar/data/1484565/000119312526071976/d106090ds8.htm) pertaining to the registration of 2,091,475 Shares issuable under the Registrant's A&R 2014 Plan, which was filed with the SEC on February 25, 2026.

On May 18, 2026, pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 5, 2026, by and among the Registrant, Neurocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Registrant (the "Merger"), with the Registrant continuing as the surviving corporation and becoming a wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in each Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under such Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of each Registration Statement and removes from registration all of the securities that remain unsold under each Registration Statement as of the date hereof, if any. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Registrant pursuant to the Registration Statements.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as [<u>Exhibit 2.1</u>](http://www.sec.gov/Archives/edgar/data/0001484565/000119312526142911/d142985dex21.htm) to the Registrant's Current Report on Form 8-K filed with the SEC on April 6, 2026.

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California on May 18, 2026.

---

| | |
|:---|:---|
| **SOLENO THERAPEUTICS, INC.** | **SOLENO THERAPEUTICS, INC.** |
| By: | /s/ Darin M. Lippoldt |
|  | Name: Darin M. Lippoldt |
|  | Title: President and Secretary |

---

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.